127 Diagnostic utility of molecular and imaging biomarkers 2 Table 11. Estimated pooled test performance of RAS mutation analysis in Bethesda III thyroid nodules reference ni test + test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Nikiforov 2011 247 19 228 0 247 (100%) 16 3 19 209 14% 46 (29-63) 99 (96-100) 32.30 (9.93-105-15) 0.55 (0.41-0.75) BeaudenonHuibregtse 2014 42 7 35 0 22 (52%) 4 1 7 10 26% 36 (11-69) 91 (59-100) 4.00 (0.53-30.33) 0.70 (0.43-1.14) Danilovic 2014 116 0 116 0 116 (100%) 0 0 23 93 20% 0 (0-15) 100 (96-100) 3.92 (0.08-192.38) 0.98 (0.93-1.05) Hwang 2015 123 47 76 0 37 (30%) 27 0 8 2 28% 77 (60-90) 100 (16-100) 4.58 (0.36-57.93) 0.28 (0.13-0.62) Nikiforov 2015 462 17 445 0 95 (21%) 11 3 11 70 5% 50 (28-72) 96 (88-99) 12.17 (3.72-39.76) 0.52 (0.34-0.79) Rossi 2015 81 4 77 0 23 (28%) 0 3 10 10 12% 0 (0-31) 77 (46-95) 0.18 (0.01-3.16) 1.27 (0.92-1.77) Yoon 2015 202 31 167 4 62 (31%) 7 4 39 12 23% 15 (6-29) 75 (48-93) 0.61 (0.20-1.81) 1.13 (0.83-1.54) Valderrabano 2016 47 0 46 1 19 (41%) 0 0 3 16 6% 0 (0-71) 100 (79-100) 4.25 (0.10-183.55) 0.90 (0.62-1.32) POOLED RESULTS 1,320 125 1,190 5 621 (47.2%) 65 14 120 422 14.0% 19.1 (4.7-53.2) 96.4 (87.7-99.0) 5.37 (0.90-31.89) 0.84 (0.62-1.13) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw